Nov 16 (Reuters) - Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers.
The move, announced on Monday by Calytrix, is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it works to diversify beyond its blockbuster diabetes and weight-loss franchise.
Lilly shares were up 1.4% in early trading.
The deal is expected to strengthen Lilly's footprint
in hematology, by adding an experimental treatment to a business that already includes the FDA-approved blood cancer medicine Jaypirca. It also follows Lilly's $2.3 billion acquisition of Ajax Therapeutics earlier this year, another bet on the blood cancer space.
The latest transaction includes an upfront payment and additional payments tied to clinical trial and regulatory milestones, Calytrix said. It did not disclose the size of the upfront payment or when the deal is expected to close.
Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells. The drug has not yet entered human clinical trials.
The treatment targets mutated calreticulin, a genetic alteration that drives disease in patients with the blood disorders. Calytrix said it is designed to attack abnormal cells driving the illness while leaving healthy blood-forming cells intact.
Current treatments manage symptoms and reduce complications rather than directly target the underlying disease-causing cells, according to the company.
Calytrix, based in Wellesley Hills, Massachusetts, was founded by J.P. Morgan Life Sciences Private Capital, the venture capital arm within J.P. Morgan Asset Management. Its investors include Westlake BioPartners and Avoro Ventures.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)













